Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20838351 | 1.00 | MAPK13 (0.33) | MAPK13MAPK12MAPK11MAPK14CYP17A1 | |
| SCHEMBL19346685 | 0.96 | GRM2 (0.32) | CYP17A1GRM2EGLN1PLK1PLK2 | |
| SCHEMBL19346487 | 0.96 | GRM2 (0.32) | CYP17A1GRM2EGLN1PLK1PLK2 | |
| SCHEMBL20838365 | 0.92 | MAPT (0.33) | EGLN1 | |
| SCHEMBL19346448 | 0.92 | MAPT (0.33) | EGLN1 | |
| SCHEMBL19346447 | 0.92 | MAPT (0.33) | EGLN1 | |
| SCHEMBL23350991 | 0.92 | GRM2 (0.32) | GRM2MAPK1 | |
| SCHEMBL20838369 | 0.91 | FFAR2 (0.32) | GRM2KIT | |
| SCHEMBL20838391 | 0.91 | GRM2 (0.32) | GRM2MAPK1 | |
| SCHEMBL19346530 | 0.91 | FFAR2 (0.32) | GRM2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426656-B1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2021-05-12 | — | — | EP | claimed |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| EP-3426656-B1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| EP-3426656-B1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| US-10858366-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2020-12-08 | — | — | US | disclosed |
| US-10858366-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2020-12-08 | — | — | US | disclosed |
| US-20200347072-A1 | Tricyclic Compounds Useful to Treat Orthomyxovirus Infections | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | disclosed |
| US-20200347072-A1 | Tricyclic Compounds Useful to Treat Orthomyxovirus Infections | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | disclosed |
| US-20190092780-A1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| US-20190092780-A1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| WO-2017153919-A1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858366-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | MAPK13 3708/4885MAPK12 2849/4885MAPK11 2848/4885 |
| US-20200347072-A1 | Tricyclic Compounds Useful to Treat Orthomyxovirus Infections | ZC3HAV1, OTC, THOP1 | MAPK13 3616/4885MAPK12 2623/4885MAPK11 2576/4885 |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | MAPK13 3616/4885MAPK12 2623/4885MAPK11 2576/4885 |
| US-20190092780-A1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, OTC, THOP1 | MAPK13 3708/4885MAPK12 2849/4885MAPK11 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.